Windtree Therapeutics, Inc. - Common Stock (NQ:WINT)

0.1100 UNCHANGED

Last Price Updated: 4:00 PM EDT, Aug 20, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Windtree Therapeutics, Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Why Is BurgerFi International (BFI) Stock Up 71% Today? ↗

July 26, 2024

BurgerFi International stock is up on Friday as investors in BFI react to it reaching a settlement agreement with Lion Point Capital, LP.

Via InvestorPlace

Why Is Windtree Therapeutics (WINT) Stock Up 116% Today? ↗

July 26, 2024

Windtree Therapeutics stock is up on Friday with heavy trading of WINT shares following an update on its clinical trials.

Via InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

July 26, 2024

Pre-market stock movers are worth diving into this morning as we check out all of the hottest news investors need to know about on Friday!

Via InvestorPlace

Why Ultra Clean Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket ↗

July 26, 2024

Via Benzinga

(WINT) - Analyzing Windtree Therapeutics's Short Interest ↗

April 23, 2024

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

May 24, 2024

We're diving into the biggest pre-market stock movers that traders need to know about on Friday morning with all of the latest news!

Via InvestorPlace

Why Windtree Therapeutics (WINT) Stock Is Getting Hammered ↗

April 18, 2024

Windtree Therapeutics shares are trading lower by 30% during Thursday's session. The company announced it approved a 1-for-18 reverse stock split of its common stock.

Via Benzinga

Why Las Vegas Sands Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

April 18, 2024

Via Benzinga

WINT Stock Earnings: Windtree Therapeutics Beats EPS for Q4 2023 ↗

April 17, 2024

WINT stock results show that Windtree Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.

Via InvestorPlace

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

February 02, 2024

Via Benzinga

Windtree Therapeutics – This Biotech Inks License Deal For Lead Candidate ↗

January 29, 2024

Craig Fraser, CEO of Windtree Therapeutics, Inc. (NASDAQ: WINT), was recently interviewed by Benzinga. Windtree is advancing late-stage interventions for cardiovascular disorders to treat patients in...

Via Benzinga

Windtree Therapeutics (NASDAQ:WINT) Eliminates $15 Million Contingent Liability To Deerfield Management Company

January 26, 2024

Via ACCESSWIRE

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

January 25, 2024

Via Benzinga

Windtree Therapeutics (NASDAQ: WINT) Eliminates $15 Million Contingent Liability To Deerfield Management Company ↗

January 25, 2024

Windtree Therapeutics (NASDAQ: WINT) announced an agreement with affiliates of biopharma investor Deerfield Management Company to fully retire a $15 million contingent liability associated with...

Via Benzinga

Week in Review: Lee’s Pharma Signs $138 Million Agreement For China Rights To Heart Failure Therapy ↗

January 20, 2024

Lee’s Pharma acquired China rights to a heart failure therapy from Windtree Therapeutics. Meanwhile, AstraZeneca signed an investment cooperation agreement with the Taizhou National Medical High-tech...

Via Talk Markets

12 Health Care Stocks Moving In Friday's After-Market Session ↗

January 19, 2024

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

January 18, 2024

Via Benzinga

Up To $138 Million in Milestones, Up To Low Double Digit Royalties: Windtree Announces Agreement To Develop And Commercialize Drug Candidates In Greater China

January 18, 2024

Via ACCESSWIRE

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

January 17, 2024

Via Benzinga

Up To $138 Million in Milestones, Up To Low Double Digit Royalties: Windtree Announces Agreement To Develop And Commercialize Drug Candidates In Greater China ↗

January 17, 2024

Greater China holds a significant, if not the world’s largest, acute heart failure patient population.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

January 17, 2024

Via Benzinga

Windtree Therapeutics Announces Reduction In Arrhythmias In A New Study With Istaroxime And A Pure SERCA2a Activator ↗

January 03, 2024

Arrhythmias are irregular heartbeats that can impact the pumping function of the heart. Patients with heart failure and cardiomyopathy are at risk for arrhythmias. Arrhythmias in these patients can be...

Via Benzinga

Istaroxime Update: Start Of Patient Dosing In Early Cardiogenic Shock SEISMiC Extension Study In Preparation For Phase 3 Readiness, Topline Data Expected Mid-2024

December 19, 2023

Via ACCESSWIRE

Istaroxime Update: Start Of Patient Dosing In Early Cardiogenic Shock SEISMiC Extension Study In Preparation For Phase 3 Readiness, Topline Data Expected mid-2024 ↗

December 18, 2023

Windtree Therapeutics, Inc. (NASDAQ: WINT) has recently enrolled the first subject in its phase 2 SEISMiC Extension Study to evaluate istaroxime in the treatment of early cardiogenic shock.

Via Benzinga

Why Immunic Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket ↗

October 10, 2023

Gainers SuperCom Ltd. (NASDAQ: SPCB) shares rose 78.4% to $0.6425 in pre-market trading, after falling 13% on Monday.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

October 10, 2023

It's time to dive into the biggest pre-market stock movers with all the most recent news moving shares on Tuesday morning!

Via InvestorPlace

Why ParaZero Technologies Shares Are Trading Higher By Over 100%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

October 09, 2023

Gainers ParaZero Technologies Ltd. (NASDAQ: PRZO) shares jumped 106% to $2.3901 after the company announced an Australian regulator approved first commercial drone flights in populated areas and near...

Via Benzinga

Windtree Therapeutics (NASDAQ:WINT) Is Developing A Multi-Asset Franchise Of Its Novel SERCA2a Activators In A Multi-Billion Dollar Market

August 16, 2023

Via ACCESSWIRE

Windtree Therapeutics (NASDAQ: WINT) Is Developing A Multi-Asset Franchise Of Its Novel SERCA2a Activators In A Multi-Billion Dollar Market ↗

August 15, 2023

Windtree Therapeutics, Inc. (NASDAQ: WINT) is a biotechnology company developing treatments for severe cardiovascular disorders.

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

September 21, 2023

During the session on Thursday, 461 stocks hit new 52-week lows.

Via Benzinga

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.